Innovent Biologics Inc. has announced the commencement of the first participant dosing in their GLORY-3 Phase 3 clinical study in China. This study focuses on evaluating the efficacy and safety of mazdutide, a dual glucagon $(GCG.UK)$ and glucagon-like peptide 1 receptor (GLP-1) receptor agonist, compared to semaglutide in adults with overweight or obesity accompanied by metabolic dysfunction-associated fatty liver disease (MAFLD). The trial aims to enroll approximately 470 participants, assessing primary endpoints such as changes in liver fat content and body weight over 48 weeks. Innovent's Senior Vice President of Clinical Development, Dr. Lei Qian, expressed confidence in mazdutide's potential to provide comprehensive metabolic benefits and a better treatment option for Chinese patients struggling with obesity-related MAFLD.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。